These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9205814)

  • 21. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.
    Garattini L; Grilli R; Scopelliti D; Mantovani L
    Pharmacoeconomics; 1995 Jan; 7(1):1-6. PubMed ID: 10155289
    [No Abstract]   [Full Text] [Related]  

  • 22. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 23. Establishing value through pharmacoeconomics: the emerging third objective in clinical trials.
    Boyer JG; Pathak DS
    Top Hosp Pharm Manage; 1994 Jan; 13(4):1-10. PubMed ID: 10130679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational studies and "real world" anesthesia pharmacoeconomics.
    Miller DR; Tierney M
    Can J Anaesth; 2002 Apr; 49(4):329-34. PubMed ID: 11927469
    [No Abstract]   [Full Text] [Related]  

  • 26. The emerging government requirement for economic evaluation of pharmaceuticals.
    Drummond M
    Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.
    Luce BR
    Pharmacoeconomics; 1993 Jan; 3(1):1-9. PubMed ID: 10146982
    [No Abstract]   [Full Text] [Related]  

  • 28. The importance of the comparator in economic evaluations: working on the efficiency frontier.
    Neyt M; Van Brabandt H
    Pharmacoeconomics; 2011 Nov; 29(11):913-6. PubMed ID: 21988290
    [No Abstract]   [Full Text] [Related]  

  • 29. A 30 year perspective of the quality of evidence published in 25 clinical journals: signs of change?
    Gnanalingham MG; Robinson SG; Hawley DP; Gnanalingham KK
    Postgrad Med J; 2006 Jun; 82(968):397-9. PubMed ID: 16754709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria.
    Postma MJ; Boersma C; Gansevoort RT
    Nephrol Dial Transplant; 2008 Apr; 23(4):1103-6. PubMed ID: 17210586
    [No Abstract]   [Full Text] [Related]  

  • 32. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
    Wang X; Wang ZF; Xie YM; Zhang W; Liao X; Chang YP;
    Chin J Integr Med; 2015 Jun; 21(6):473-80. PubMed ID: 24671571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trial and economic evaluation.
    Jain S; Arora NK
    Indian J Pediatr; 2000 May; 67(5):363-8. PubMed ID: 10885210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
    Al Kadour A; Marridi WA; Al-Badriyeh D
    Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
    Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
    Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts?
    Stearns SC; Drummond M
    Med Care; 2003 Jan; 41(1):1-3. PubMed ID: 12544536
    [No Abstract]   [Full Text] [Related]  

  • 37. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.
    Hay JW; Yu WM
    Value Health; 2000; 3(3):181-5. PubMed ID: 16464182
    [No Abstract]   [Full Text] [Related]  

  • 38. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What's cost-effective in cancer care?
    Cancer Discov; 2011 Nov; 1(6):OF1-2. PubMed ID: 22586658
    [No Abstract]   [Full Text] [Related]  

  • 40. Improving drug trials for mild to moderate Alzheimer's disease.
    Hogan DB
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S97-102. PubMed ID: 17469691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.